Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer

• Prif Awduron: Neeraj Gupta (Awdur), Philippe B. Pierrillas (Awdur), Michael J. Hanley (Awdur), Steven Zhang (Awdur), Paul M. Diderichsen (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wiley, 2022-06-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Mobocertinib is an oral tyrosine kinase inhibitor approved for treatment of patients with locally advanced or metastatic non‐small cell lung cancer (mNSCLC) with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum‐based...